Drug intelligence / Profile preview

TAK-361S

Development stage: Discontinued
Lead developer: Takeda
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

**TAK-361S** was Takeda's investigational pediatric combination vaccine designed to prevent diphtheria, pertussis, tetanus, and poliomyelitis. It combined diphtheria-tetanus-acellular pertussis vaccine components with Sabin-strain inactivated poliovirus vaccine and was evaluated as a repeated subcutaneous vaccination regimen in healthy Japanese children aged 3–67 months in a Phase 2 dose-finding study. Takeda voluntarily discontinued development of the program in February 2015 following vaccine-portfolio prioritization. ([jrct.mhlw.go.jp](https://jrct.mhlw.go.jp/en-latest-detail/jRCT2080221634))

Targets

Diphtheria toxinPV3 (Sabin) (Poliovirus type 3 antigen)

Beyond the preview

Go deeper on TAK-361S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-361S.

Explore the full profile